Revista do Instituto de Medicina Tropical de São Paulo
On-line version ISSN 1678-9946
IOSHIMOTO, Luzia M. et al. Safety and immunogenicity of hepatitis B vaccine ButaNG in adults. Rev. Inst. Med. trop. S. Paulo [online]. 1999, vol.41, n.3, pp.191-193. ISSN 1678-9946. http://dx.doi.org/10.1590/S0036-46651999000300011.
Recombinant yeast-derived hepatitis B vaccine manufactured by Instituto Butantan was administered in two groups of adult volunteers (I, II) following two different schedules of immunization. In the first trial (10 mg doses and 0, 1, 3 months vaccination schedule) 106 individuals completed the full immunization program. The results of seroconversion by age group varied from 70 to 100% and the GMT from 46.5 to 124.9 mIU mL-1. In the second trial with 68 individuals (for dosage comparison and 0, 1, 6 months vaccination schedule) indicated that the vaccine formulated in 20 mg was more effective than in 10 mg. The adverse reactions observed in the vaccinees were less frequent than the ones previously found since the introduction of similar vaccines.
Keywords : Hepatitis B vaccine; Clinical trials.